Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2015
October 05 2015 - 4:05PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced estimated third
quarter revenue of approximately $550 million, a 14% increase
compared to $481 million in the third quarter of 2014 and
18% growth on a constant currency basis. This estimate, which is
unaudited, is based on management's preliminary financial
analysis.
“Demand for sequencing consumables and the HiSeq family of
instruments remained strong during the quarter, while instrument
sales in the desktop family underperformed our expectations,”
stated Jay Flatley, CEO. “Geographically, we were disappointed with
instrument sales in Europe and continued weakness in the
Asia-Pacific region. Despite this 3% shortfall to expectations, our
competitive position and product development pipeline are as strong
as ever. The new markets we are targeting are enormous, and will
support significant revenue growth for Illumina in 2016 and beyond,
consistent with our prior long-term guidance.”
Financial outlook and guidance
For fiscal 2015,
the company now projects approximately 18% total
revenue growth (21% on a constant currency basis,
assuming current exchange rates) and fourth quarter revenue of
approximately $570 million. Updated GAAP and non-GAAP EPS guidance
will be provided when reporting third quarter results on October
20, 2015.
Pre-Announcement Conference Call Details
A brief conference call to discuss preliminary third quarter
results will be held today, October 5, 2015, at 1:30 p.m. Pacific
Time (4:30 p.m. Eastern Time). Interested parties may listen to the
call by dialing 800-237-9752 (passcode: 47160581), or if outside
North America by dialing +1-617-847-8706 (passcode: 47160581).
Individuals may access the live teleconference in the Investor
Relations section of Illumina’s web site under the “Company” tab at
www.illumina.com.
A replay of the conference call will be available from 5:30 p.m.
Pacific Time (8:30 p.m. Eastern Time) through October 12, 2015 by
dialing 888-286-8010 (passcode: 61114080), or if outside North
America by dialing +1-617-801-6888 (passcode: 61114080).
Third Fiscal Quarter Results Conference Call Details
The company also announced that results for third fiscal quarter
2015 will be issued following the close of market on Tuesday,
October 20, 2015. On the same day, at 2:00 p.m. Pacific Time (5:00
p.m. Eastern Time) Jay Flatley, Chief Executive Officer, Francis
deSouza, President, and Marc Stapley, Senior Vice President and
Chief Financial Officer, will host a conference call to discuss
financial and operating results.
Interested parties may listen to the call by dialing
866-318-8619 (passcode: 77482042), or if outside North America by
dialing +1-617-399-5138 (passcode: 77482042). Individuals may
access the live teleconference in the Investor Relations section of
Illumina’s web site under the “Company” tab at
www.illumina.com.
A replay of the conference call will be available from 6:00 p.m.
Pacific Time (9:00 p.m. Eastern Time) on October 20, 2015 through
October 27, 2015 by dialing 888-286-8010 (passcode: 76392714), or
if outside North America by dialing +1-617-801-6888 (passcode:
76392714).
Use of forward-looking statements
This release contains projections, information about our
financial outlook, earnings guidance, and other forward-looking
statements that involve risks and uncertainties. These
forward-looking statements are based on our expectations as of the
date of this release and may differ materially from actual future
events or results. Among the important factors that could cause
actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop
and commercialize our instruments and consumables and to deploy new
products, services, and applications, and expand the markets, for
our technology platforms; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) our ability to successfully
identify and integrate acquired technologies, products, or
businesses; (iv) our expectations and beliefs regarding future
conduct and growth of the business and the markets in which we
operate; (v) challenges inherent in developing, manufacturing, and
launching new products and services; and (vi) the application of
generally accepted accounting principles, which are highly complex
and involve many subjective assumptions, estimates, and judgments,
together with other factors detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to
update these forward-looking statements, to review or confirm
analysts’ expectations, or to provide interim reports or updates on
the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow
@illumina.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151005006601/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Eric Endicott,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024